Cargando…

Immune Biomarkers in the Peripheral Blood and Tumor Microenvironment of Classical Hodgkin Lymphoma Patients in Relation to Tumor Burden and Response to Treatment

In classical Hodgkin lymphoma (cHL), the malignant cells represent only a small fraction of the tumor. Yet, they orchestrate a lymphocyte-dominated tumor microenvironment (TME) that supports their survival and growth. The systemic effects of this local immunomodulation are not fully elucidated. Here...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mulder, Tom A., Andersson, Maria L., Peña-Pérez, Lucía, Heimersson, Kia, Xagoraris, Ioanna, Wahlin, Björn E., Månsson, Robert, Hansson, Lotta, Rassidakis, Georgios, Palma, Marzia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9619233/ https://www.ncbi.nlm.nih.gov/pubmed/36325271 http://dx.doi.org/10.1097/HS9.0000000000000794

Ejemplares similares

P032: Circulating immune biomarkers in classical Hodgkin lymphoma in relation to tumor burden and response to treatment.
por: Mulder, Tom A., et al.
Publicado: (2022)

P1283: CIRCULATING IMMUNE CELLS IN CLASSICAL HODGKIN LYMPHOMA IN RELATION TO TUMOR BURDEN AND TREATMENT
por: Mulder, T. A., et al.
Publicado: (2022)

P053: The cGAS-STING anti-tumor immune response pathway as a potential therapeutic target in classical Hodgkin Lymphoma (cHL)
por: Xagoraris, Ioanna, et al.
Publicado: (2022)

P052: Targeting CSN5/JAB1 oncogene in classical Hodgkin Lymphoma (cHL)
por: Xagoraris, Ioanna, et al.
Publicado: (2022)

P609: EFFECT OF LONG-TERM ZANUBRUTINIB TREATMENT ON T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB-3111-304 AND 305 TRIALS.
por: Andersson, Maria, et al.
Publicado: (2023)

Real‐world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000–2014, focusing on patients aged >60 years
por: Wahlin, Björn Engelbrekt, et al.
Publicado: (2021)

Temporary cessation of ibrutinib results in reduced grade 3‐4 infections and durable remissions—Interim analysis of an on‐off‐repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia
por: Lundin, Jeanette, et al.
Publicado: (2021)

Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas
por: Xagoraris, Ioanna, et al.
Publicado: (2022)

P1304: THE NOVEL TUMOR SUPPRESSOR SAMHD1 CONTRIBUTES TO ANTI-TUMOR RESPONSES IN A CGAS-STING-DEPENDENT OR INDEPENDENT PATHWAY IN HODGKIN LYMPHOMA (HL)
por: Xagoraris, I., et al.
Publicado: (2022)

Targeting the Immune Microenvironment in Lymphomas of B-Cell Origin: From Biology to Clinical Application
por: Mulder, Tom A., et al.
Publicado: (2019)

Ibrutinib Has Time-dependent On- and Off-target Effects on Plasma Biomarkers and Immune Cells in Chronic Lymphocytic Leukemia
por: Mulder, Tom A., et al.
Publicado: (2021)

T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers
por: Palma, Marzia, et al.
Publicado: (2017)

Acquired Natural Killer Cell Dysfunction in the Tumor Microenvironment of Classic Hodgkin Lymphoma
por: Chiu, Jodi, et al.
Publicado: (2018)

Identification of a novel monocytic phenotype in Classic Hodgkin Lymphoma tumor microenvironment
por: Post, Ginell R., et al.
Publicado: (2019)

Checkpoint protein expression in the tumor microenvironment defines the outcome of classical Hodgkin lymphoma patients
por: Karihtala, Kristiina, et al.
Publicado: (2022)

PB1924: INCIDENCE OF CARDIOVASCULAR AND BLEEDING EVENTS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL) TREATED WITH IBRUTINIB – A RETROSPECTIVE ANALYSIS ON CONSECUTIVE PATIENTS FROM A WELL-DEFINED REGION.
por: Andersson, Maria, et al.
Publicado: (2023)

The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein–Barr virus presence and location within the tumor
por: Wu, R, et al.
Publicado: (2016)

Immune and Inflammatory Cells of the Tumor Microenvironment Represent Novel Therapeutic Targets in Classical Hodgkin Lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2019)

The Tumor Microenvironment in Classic Hodgkin’s Lymphoma in Responder and No-Responder Patients to First Line ABVD Therapy
por: Tamma, Roberto, et al.
Publicado: (2023)

Optimizing checkpoint inhibitors therapy for relapsed or progressive classic Hodgkin lymphoma by multiplex immunohistochemistry of the tumor microenvironment
por: Carbone, Antonino, et al.
Publicado: (2019)

The Prognostic Value of Eight Immunohistochemical Markers Expressed in the Tumor Microenvironment and on Hodgkin Reed-Sternberg Cells in Pediatric Patients With Classical Hodgkin Lymphoma
por: Zijtregtop, Eline A. M., et al.
Publicado: (2022)

P038: HLA expression patterns of Hodgkin-Reed-Sternberg cells shape a spatially arranged tumor microenvironment in classical Hodgkin lymphoma
por: Müller-Meinhard, Berit, et al.
Publicado: (2022)

Macrophage Polarization Reflects T Cell Composition of Tumor Microenvironment in Pediatric Classical Hodgkin Lymphoma and Has Impact on Survival
por: Barros, Mário H. M., et al.
Publicado: (2015)

Immune targeting of the microenvironment in classical Hodgkin’s lymphoma: insights for the hematologist
por: Carreau, Nicole A., et al.
Publicado: (2019)

Prognostic Markers within the Tumour Microenvironment in Classical Hodgkin Lymphoma
por: Martynchyk, Arina, et al.
Publicado: (2023)

Hodgkin's Lymphomas: A Tumor Recognized by Its Microenvironment
por: Montes-Moreno, S.
Publicado: (2011)

NFATc1 is Suppressed in Tumor Microenvironment of Hodgkin Lymphoma
por: Murti, Krisna, et al.
Publicado: (2021)

Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It
por: Aldinucci, Donatella, et al.
Publicado: (2019)

Plasma cells in classical Hodgkin lymphoma: a new player in the microenvironment?
por: Visser, Lydia
Publicado: (2018)

Inflammatory microenvironment in classical Hodgkin’s lymphoma with special stress on mast cells
por: Ribatti, Domenico, et al.
Publicado: (2022)

Unraveling the Immune Microenvironment in Classic Hodgkin Lymphoma: Prognostic and Therapeutic Implications
por: Georgoulis, Vasileios, et al.
Publicado: (2023)

ALK Negative Inflammatory Myofibroblastic Tumor Synchronous with Classical Hodgkin Lymphoma
por: Sandoval, Letícia, et al.
Publicado: (2019)

Tumor-associated macrophages in classical Hodgkin lymphoma: hormetic relationship to outcome
por: Werner, Laura, et al.
Publicado: (2020)

Immune-Proteome Profiling in Classical Hodgkin Lymphoma Tumor Diagnostic Tissue
por: Gholiha, Alex Reza, et al.
Publicado: (2021)

The Tumor Suppressive mir-148a Is Epigenetically Inactivated in Classical Hodgkin Lymphoma
por: Paczkowska, Julia, et al.
Publicado: (2020)

Tackling the dysregulated immune-checkpoints in classical Hodgkin lymphoma: bidirectional regulations between the microenvironment and Hodgkin/Reed-Sternberg cells
por: Cellini, Alessandro, et al.
Publicado: (2023)

P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2022)

Intracerebral manifestation of iatrogenic, immunodeficiency-associated polymorphic B-LPD with morphology mimicking Hodgkin lymphoma: a case report and literature review
por: Saft, Leonie, et al.
Publicado: (2022)

PDL1 shapes the classical Hodgkin lymphoma microenvironment without inducing T-cell exhaustion
por: Taylor, Joseph G., et al.
Publicado: (2022)

P091: Early analysis of the PRO-Hodgkin study: Clinical investigation of pencil beam scanning proton treatment in Hodgkin lymphoma patients
por: Goldkuhl, Christina, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hsb8hu8b6arlgkktp3dimr7q5v